Please use this identifier to cite or link to this item:
|Title:||Targeted therapy in prostate cancer.|
|Epworth Authors:||Corcoran, Niall|
|Other Authors:||Gleave, M.|
|Keywords:||Epworth Prostate Centre, Epworth HealthCare Richmond, Melbourne, Vic., Australia|
Molecular Targeted Therapy
|Citation:||Histopathology. 2012 Jan;60(1):216-31|
|Abstract:||The therapeutic approach to advanced prostate cancer has seen greater changes in the last 7 years than it did in the preceding 70. Although only one of the newly approved agents that improve overall survival is a targeted agent, it is a validation of the method of pathway analysis and drug design in delivering novel, clinically usable agents. As our knowledge of the molecular circuitry of tumour invasion, metastases and treatment resistance has become more refined, the number of new, potentially useful, targets has grown exponentially. This is reflected in the vast array of diverse targeted agents that are currently being evaluated in human trials. In this review, we briefly describe some of the key pathways that are involved in the evolution of the prostate cancer 'lethal phenotype', and review the clinical activity of some of the newly approved targeted therapies or those in advanced phases of clinical development.|
|Affiliated Organisations:||Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia|
|Type of Clinical Study or Trial:||Review|
|Appears in Collections:||Cancer Services|
Epworth Prostate Centre
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.